<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030082</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068941</org_study_id>
    <secondary_id>NCI-01-C-0215</secondary_id>
    <nct_id>NCT00030082</nct_id>
    <nct_alias>NCT00021606</nct_alias>
  </id_info>
  <brief_title>Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer</brief_title>
  <official_title>A Phase I Study of Hepatic Arterial Infusion of Escalating Dose Melphalan With Venous Filtration for Metastatic Unresectable Cancers of the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the&#xD;
      affected area directly around the tumor may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of hepatic arterial infusion with melphalan&#xD;
      in treating patients who have unresectable liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of hepatic arterial&#xD;
           infusion with melphalan in patients with unresectable liver cancer.&#xD;
&#xD;
        -  Determine the regional and systemic toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients undergo percutaneous hepatic arterial infusion, using a double balloon catheter in&#xD;
      the inferior vena cava to isolate circulation to the liver, with melphalan over 30 minutes on&#xD;
      day 1. Treatment may be repeated when all toxic effects are grade 2 or less. Patients undergo&#xD;
      staging at 4 weeks after completion of the second treatment. Patients may receive 2&#xD;
      additional treatments.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of melphalan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 12 additional&#xD;
      patients are treated with melphalan at the recommended dose.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 4 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Liver Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable cancer of the parenchyma of the&#xD;
             liver&#xD;
&#xD;
          -  Liver metastases allowed&#xD;
&#xD;
          -  Limited unresectable extrahepatic disease (including but not limited to the following)&#xD;
             is allowed provided the life-threatening component of progressive disease is in liver:&#xD;
&#xD;
               -  Up to 4 pulmonary nodules each less than 1 cm in diameter&#xD;
&#xD;
               -  Retroperitoneal lymph nodes less than 3 cm in diameter&#xD;
&#xD;
               -  Fewer than 10 skin or subcutaneous metastases less than 1 cm in diameter&#xD;
&#xD;
               -  Asymptomatic bone metastases that have been or can be palliated with radiotherapy&#xD;
&#xD;
               -  Solitary metastasis to any site that can be resected&#xD;
&#xD;
          -  Prior therapy with intrahepatic perfusion with or without hepatic arterial infusion&#xD;
             with floxuridine is allowed provided patient had a radiographic partial response of&#xD;
             3-months duration&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  14 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,300/mm^3&#xD;
&#xD;
          -  Hematocrit greater than 27%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  PT within 2 seconds of upper limit of normal&#xD;
&#xD;
          -  No biopsy-proven cirrhosis with evidence of portal hypertension by history, endoscopy,&#xD;
             or radiologic study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior congestive heart failure with LVEF less than 40%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  No other chronic pulmonary disease&#xD;
&#xD;
          -  FEV_1 at least 30% of predicted&#xD;
&#xD;
          -  DLCO at least 40% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Weight greater than 35 kg&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infections&#xD;
&#xD;
          -  No severe allergic reaction to iodine contrast not controlled by antihistamines or&#xD;
             steroids&#xD;
&#xD;
          -  No known prior hypersensitivity reaction to melphalan&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 1 month since prior biologic therapy for the malignancy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior chemotherapy for the malignancy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior radiotherapy for the malignancy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent chronic anticoagulants&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Richard Alexander, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>January 30, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

